Hansa Biopharma
Market Cap
kr5.1b
Last Updated
2019/10/14 20:56 UTC
Data Sources
Company Financials +
Executive Summary
Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases.
Snowflake
Fundamentals
Flawless balance sheet with limited growth.
Share Price & News
How has Hansa Biopharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.5%
HNSA
1.8%
SE Biotechs
1.9%
SE Market
1 Year Return
-56.8%
HNSA
-18.0%
SE Biotechs
9.6%
SE Market
Return vs Industry: HNSA underperformed the Swedish Biotechs industry which returned -18% over the past year.
Return vs Market: HNSA underperformed the Swedish Market which returned 9.6% over the past year.
Shareholder returns
| HNSA | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.5% | 1.8% | 1.9% |
| 30 Day | -12.1% | -1.9% | -0.3% |
| 90 Day | -29.9% | -11.7% | 0.7% |
| 1 Year | -56.8%-56.8% | -17.5%-18.0% | 14.3%9.6% |
| 3 Year | 74.7%74.7% | 29.5%19.2% | 31.5%11.9% |
| 5 Year | 477.8%448.7% | 66.9%68.0% | 66.2%30.8% |
Price Volatility Vs. Market
How volatile is Hansa Biopharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Kind Of Investor Owns Most Of Hansa Biopharma AB (publ) (STO:HNSA)?4 weeks ago | Simply Wall St
How Many Hansa Biopharma AB (publ) (STO:HNSA) Shares Have Insiders Sold, In The Last Year?1 month ago | Simply Wall St
Hansa Biopharma (STO:HNSA) Shareholders Have Enjoyed A Whopping 605% Share Price GainValuation
Is Hansa Biopharma undervalued compared to its fair value and its price relative to the market?
6.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate HNSA's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate HNSA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HNSA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: HNSA is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate HNSA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HNSA is overvalued based on its PB Ratio (6.8x) compared to the SE Biotechs industry average (3.8x).
Next Steps
Future Growth
How is Hansa Biopharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
30.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HNSA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HNSA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HNSA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HNSA's revenue (64.3% per year) is forecast to grow faster than the Swedish market (4.5% per year).
High Growth Revenue: HNSA's revenue (64.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if HNSA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Hansa Biopharma performed over the past 5 years?
-42.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: HNSA is unprofitable, and losses have increased over the past 5 years at a rate of -42.3% per year.
Accelerating Growth: Unable to compare HNSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HNSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.4%).
Return on Equity
High ROE: HNSA has a negative Return on Equity (-39.39%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: HNSA is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: HNSA is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Hansa Biopharma's financial position?
Financial Position Analysis
Short Term Liabilities: HNSA's short term assets (SEK767.5M) exceeds its short term liabilities (SEK49.7M)
Long Term Liabilities: HNSA's short term assets (767.5M) exceeds its long term liabilities (12.7M)
Debt to Equity History and Analysis
Debt Level: HNSA's debt to equity ratio (0.1%) is considered satisfactory
Reducing Debt: HNSA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: HNSA has a low level of unsold assets or inventory.
Debt Coverage by Assets: HNSA's debt is covered by short term assets (assets are 1035.784070x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HNSA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HNSA has sufficient cash runway for 1.145498 years if free cash flow continues to reduce at historical rates of -39.7% each year.
Next Steps
Dividend
What is Hansa Biopharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate HNSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate HNSA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if HNSA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HNSA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HNSA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
What is the CEO of Hansa Biopharma's salary, the management and board of directors tenure and is there insider trading?
0.4yrs
Average management tenure
CEO
Søren Tulstrup (54yo)
1.6yrs
Tenure
Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Medical AB (publ) since March 20, 2018. Mr. Tulstrup served as the Chief Executive Officer of Vifor Pharma Ltd. since Augus ...
Management Age and Tenure
0.4yrs
Average Tenure
52yo
Average Age
Experienced Management: HNSA's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Age and Tenure
1.4yrs
Average Tenure
64.5yo
Average Age
Experienced Board: HNSA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 1,900 |
| Max Price | kr164.80 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 2,500 |
| Max Price | kr179.18 |
| Entity | Individual |
| Role | Head of Human Resources Vice President of Global Human Resources |
| Shares | 360 |
| Max Price | kr221.73 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 10,000 |
| Max Price | kr174.42 |
| Entity | Individual |
| Role | Chief Executive Officer President & CEO |
| Shares | 5,000 |
| Max Price | kr185.00 |
| Entity | Individual |
| Shares | 20,000 |
| Max Price | kr180.00 |
Ownership Breakdown
Management Team
Søren Tulstrup (54yo)
President & CEO
- Tenure: 1.6yrs
Christian Kjellman (52yo)
Senior VP of Research & Development and Chief Scientific Officer
- Tenure: 0.3yrs
Henk J. van Troostwijk (54yo)
Senior VP & Chief Commercial Officer
- Tenure: 0.3yrs
Donato Spota (48yo)
CFO & Senior VP
- Tenure: 0.4yrs
Eva-Maria Joed (50yo)
Vice President of Finance & Administration
- Tenure: 0.4yrs
Anne Lanner
Vice President of Global Human Resources
- Tenure: 0.8yrs
Klaus Sindahl
Head of Investor Relations
- Tenure: 0yrs
Board Members
Birgit Norinder (71yo)
Director
- Tenure: 7.8yrs
- Compensation: kr467.00k
Ulf Wiinberg (61yo)
Chairman of the Board
- Tenure: 1.6yrs
- Compensation: kr2.56m
Anders Pedersen (68yo)
Director
- Tenure: 1.4yrs
- Compensation: kr210.00k
Eva Nilsagård (55yo)
Director
- Tenure: 0.4yrs
Andreas Eggert
Director
- Tenure: 1.4yrs
- Compensation: kr204.00k
Gunnar Tufveson
Chairman of European Medical Advisory Board in Transplantation
- Tenure: 0yrs
Kathryn Wood
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation
- Tenure: 0yrs
Christophe Legendre
Member of European Medical Advisory Board in Transplantation
- Tenure: 0yrs
Stanley Jordan
Chairman of US Medical Advisory Board in Transplantation
- Tenure: 0yrs
Robert Montgomery
Member of US Medical Advisory Board in Transplantation
- Tenure: 0yrs
Company Information
Hansa Biopharma AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hansa Biopharma AB (publ)
- Ticker: HNSA
- Exchange: OM
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr5.139b
- Shares outstanding: 40.03m
- Website: https://www.hansabiopharma.com
Number of Employees
Location
- Hansa Biopharma AB (publ)
- Scheelevägen 22
- Lund
- Skåne County
- 222 63
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HNSA | OM (OMX Nordic Exchange Stockholm) | Yes | Class B Shares | SE | SEK | Oct 2007 |
| HNSB.F | OTCPK (Pink Sheets LLC) | Yes | Class B Shares | US | USD | Oct 2007 |
| 0RC7 | LSE (London Stock Exchange) | Yes | Class B Shares | GB | SEK | Oct 2007 |
| 24H | DB (Deutsche Boerse AG) | Yes | Class B Shares | DE | EUR | Oct 2007 |
Biography
Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. The company’s lead drug candidate is Immunogl ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/14 20:56 |
| End of Day Share Price | 2019/10/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.